| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Kinnate Biopharma Inc. | Director | Common Stock | 0 | $0 | $2.59 | Apr 3, 2024 | Direct |
| Clovis Oncology, Inc. | Director | Stock Option (right to buy) | 42.2K | Jun 10, 2021 | Direct | ||
| Checkmate Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 0 | May 31, 2022 | Direct | ||
| Kinnate Biopharma Inc. | Director | Stock Option (right to buy) | 0 | Apr 3, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | Apr 3, 2024 | 7 | $0 | 4 | Apr 5, 2024 | Director |
| KNTE | Kinnate Biopharma Inc. | Jun 12, 2023 | 1 | $0 | 4 | Jun 13, 2023 | Director |
| KNTE | Kinnate Biopharma Inc. | Jun 13, 2022 | 1 | $0 | 4 | Jun 15, 2022 | Director |
| CMPI | Checkmate Pharmaceuticals, Inc. | May 31, 2022 | 3 | $0 | 4 | May 31, 2022 | Director |
| CMPI | Checkmate Pharmaceuticals, Inc. | Jun 16, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |
| KNTE | Kinnate Biopharma Inc. | Jun 11, 2021 | 1 | $0 | 4 | Jun 14, 2021 | Director |
| CLVS | Clovis Oncology, Inc. | Jun 10, 2021 | 1 | $0 | 4 | Jun 11, 2021 | Director |